A new bandage to prevent infections in burn wounds
A Compliant Superhydrophobic Antimicrobial Photodynamic Therapy Bandage for the Prevention of Multidrug Resistant Wound Infections
This study is testing a new type of bandage that helps prevent infections in burn wounds by using light to kill harmful bacteria, making it safer and more effective for healing without relying on traditional antibiotics.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Singleto2 Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Summit, UNITED STATES) |
| Project ID | NIH-10920772 on NIH RePORTER |
What this research studies
This research focuses on developing an innovative bandage designed to prevent infections caused by multidrug-resistant bacteria in burn wounds. The bandage utilizes antimicrobial photodynamic therapy (aPDT) by delivering airborne singlet oxygen, which effectively kills bacteria without introducing drugs into the wound. This approach minimizes the risk of bacterial resistance and enhances the healing process. The bandage's unique superhydrophobic design allows for controlled delivery of treatment while reducing direct contact with the wound.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with burn wounds who are at risk of developing multidrug-resistant infections.
Not a fit: Patients with non-burn related wounds or those not at risk for multidrug-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of infections in burn patients, leading to better recovery outcomes.
How similar studies have performed: Previous research has shown promise with antimicrobial photodynamic therapy, but this specific approach using a superhydrophobic bandage is novel.
Where this research is happening
Summit, UNITED STATES
- Singleto2 Therapeutics, LLC — Summit, United States (Active)
Researchers
- Principal investigator: Xu, Qianfeng — Singleto2 Therapeutics, LLC
- Study coordinator: Xu, Qianfeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.